Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia-Reference-Cited by-同舟云学术

Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Published:2016-04-21 Issue:8 Volume:63 Page:1332-1338
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Samis Jill¹²,Lee Paul³,Zimmerman Donald¹²,Arceci Robert J.⁴,Suttorp Meinolf⁵,Hijiya Nobuko²³

Affiliation:

1. Division of Pediatric Endocrinology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois

2. Department of Pediatrics; Northwestern University Feinberg School of Medicine; Chicago Illinois

3. Division of Pediatric Hematology Oncology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois

4. Department of Child Health; The Ron Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital; University of Arizona College of Medicine, Phoenix, Arizona

5. Pediatric Hematology, Oncology & Stem Cell Transplantation, Department of Pediatrics, Children's Hospital; Technical University of Dresden; Dresden Germany

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.26028/fullpdf

Reference82 articles.

1. Surveillance Research Program NCI http://seer.cancer.gov/faststats/

2. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group;Champagne;Pediatr Blood Cancer,2011

3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome;Druker;N Engl J Med,2001

4. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial;Millot;J Clin Oncol,2011

5. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia;Mathisen;Blood Rev,2014

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review;Current Pharmaceutical Design;2024-09

2. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?;Expert Review of Clinical Pharmacology;2024-02-12

3. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach;Current Oncology Reports;2024-02-10

4. Room To Grow: Bosutinib Approved for Newly Diagnosed or Relapsed/Intolerant Pediatric Chronic Myeloid Leukemia;The Hematologist;2024

5. Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort;British Journal of Haematology;2023-12-14